Combining a low-dose DOAC with an antiplatelet agent significantly reduces the risk of cardioembolic strokes and embolic stroke of undetermined source (ESUS) in patients with systemic atherosclerotic disease, a study shows. An analysis of stroke subtypes in the COMPASS trial of low dose rivaroxaban (2.5mg twice daily) and aspirin (100mg daily) showed that the combination ...
Rivaroxaban-aspirin effect on stroke subtypes revealed
By Michael Woodhead
30 Sep 2019